Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 28

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 28
---
 Nominating Committee has determined that we and our stockholders continue to be best served by maintaining our current classified board structure, stockholder voting standards, and other corporate defensive measures, and we believe these protections provide crucial stability to our Board and our company to allow long-term execution of our strategy.

We also believe that support for Dr. Fischer may have been further impacted due to overboarding concerns from certain proxy advisory firms and institutional investors based on his role as President and Chief Executive Officer of Adverum Biotechnologies, Inc., his service on the board of directors of ATAI Life Sciences NV, and his service on our Board. Our Nominating Committee has evaluated Dr. Fischer’s time commitments, and following such review, we continue to believe that Dr. Fischer is able to devote sufficient time and attention to his duties and to fulfill his responsibilities as a member of our Board. We also believe that his technical medical knowledge, experience with biopharmaceuticals, first-hand understanding of our industry and continued dedication to our company continue to make him an important member of our Board and allow us to execute on our commercial strategy, which we believe generates long-term value for our stockholders.

Neither the anti-takeover provisions in our governing documents, nor Dr. Fischer’s ability to devote sufficient time and attention to our Board, were defining topics in our stockholder engagement following the 2024 Annual Meeting. Nevertheless, we are committed to continually evaluating our corporate governance framework and Board composition and will continue to engage with stockholders on these important topics.

#### 24Mirum Pharmaceuticals2025 Proxy Statement

### TABLE OF CONTENTS
Information Regarding the Board of Directors and Corporate Governance

#### Stockholder Communications With the Board
The Board has adopted a formal process by which stockholders may communicate with the Board or any of its directors. Stockholders who wish to communicate with the Board may do so by sending written communications addressed to 989 East Hillsdale Boulevard, Suite 300, Foster City, California 94404, Attention: Corporate Secretary. Such written communications must set forth the name and address of the stockholder on whose behalf the communication is sent and the number of shares of our capital stock that are owned beneficially by such stockholder as of the date of the communication. All communications will be compiled by our Corporate Secretary and submitted to the Board or the individual directors on a periodic basis.

These communications will be reviewed by our Corporate Secretary, who will determine whether the communication should be presented to the Board. The purpose of this screening is to allow the Board